Fairvalue-Calculator Fairvalue-Calculator
EN DE

BiOptic Inc (6850) Fair Value & Analysis

Healthcare · TW · Market cap 1.1B TWD

Price34.80 TWD
Fair Value12.91 TWD
Upside-62.9%
Quality92/100
Evidence: High Range 8.48 TWD – 17.17 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

BiOptic Inc (6850) currently trades at 34.80 TWD, while our model-based Fair Value estimate is 12.91 TWD — implying the stock looks roughly 62.9% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits. BiOptic Inc.was founded in 1993 and is headquartered in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is BiOptic Inc (6850) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 12.91 TWD versus a price of 34.80 TWD — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6850?
Our 21-model fair value for BiOptic Inc is 12.91 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 34.80 TWD.
What is the quality score of 6850?
BiOptic Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.